CN101227923A

CN101227923A - Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue

Info

Publication number: CN101227923A
Application number: CNA2006800269740A
Authority: CN
Inventors: G·C·伯吉斯
Original assignee: Pfizer Inc
Current assignee: Pfizer Ltd; Pfizer Inc
Priority date: 2005-07-08
Filing date: 2006-06-28
Publication date: 2008-07-23
Also published as: KR20080017088A; CA2613017A1; WO2007007145A2; US20100119517A1; RU2007149268A; EP1904103A2; AU2006268045A1; MX2008000129A; JP2007016030A; BRPI0612645A2; AR055072A1; TW200740845A; ZA200711163B; IL188318A0; WO2007007145A3

Abstract

Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue The invention relates to the use of an anti-MAdCAM antibody for the manufacture of a medicament for the treatment of coeliac disease and/or tropical sprue. Methods of treatment for coeliac disease and/or tropical sprue using a therapeutically effective amount of an anti-MAdCAM antibody are also included.

Description

The purposes of anti-MAdCAM antibody in treatment celiac disease and ceylon sore mouth

Technical field

The present invention relates to anti-MAdCAM antibody and be used for the treatment of purposes in the medicine of celiac disease and/or ceylon sore mouth in preparation.

Prior art

(Mucosal addressin cell adhesinmolecule MAdCAM) is the member of cell adhesion receptor immunoglobulin superfamily to the cell adhesion molecule of mucosa addressin.It is to participate in one of adhesion molecule of raising to tissue in lymphocyte (when needing) by interacting with integrin molecule at lymphocytic cell surface.

Show, can suppress MAdCAM and its integrin binding partners (α ₄β ₇) bonded antibody, for example anti-MAdCAM antibody (MECA-367 for example; No. 5403919, United States Patent (USP), United States Patent (USP) 5538724) or anti--α ₄β ₇Antibody (Act-1 for example; United States Patent (USP) 6551593), can suppress leukocyte, and therefore help treating inflammatory bowel (IBD) to the oozing out of inflammatory bowel portion.

Yet, in people patient, do not have a therapeutic use such as anti-MAdCAM antibodies such as MECA-367; MECA-367 can be in conjunction with mice MAdCAM, but how many affinitys people MAdCAM molecule is not demonstrated.In addition, as rat antibody, it can cause immunne response and therefore be not suitable for therapeutic use in people patient.Once set forth mouse monoclonal antibody (WO 96/24673), but these also might have immunogenicity in the people at people MAdCAM.Recently, developed people and primates MAdCAM are had the whole person Anti-Human MAdCAM antibody that can be used for treating of strong specificity and affinity and be set forth among the WO 2005/067620.

MAdCAM and α have been proposed ₄β ₇The interactional inhibitor of integrin (for example barrier anti-MAdCAM antibody or anti-α ₄β ₇Alpha 2 integrin antibodies, MLN02 for example, it is humanization Act-1, is set forth in WO 01/078779) can be used for treating inflammatory bowel (IBD).Yet, have now found that this interaction inhibitor that comprises the MAdCAM blocking antibody also can be used for treating celiac disease and ceylon sore mouth.

Celiac disease (also being called seitan sensitivity enteropathy or sprue) is a kind of small intestinal disease.In the UK ﹠ EURO and the U.S., 300 philtrums just have 1 people influenced by this disease.Celiac disease is a kind of common disease, and can have influence on any age anyone.It is believed that it is more common in the male, but might appear at equally among male and the women.

Seitan is the mixture of two kinds of protein (gliadin and glutenin), is present in Semen Tritici aestivi, Fructus Hordei Vulgaris and the rye (Secale cereale L.).It can react with small intestinal, causes damage thereby attack fragile responsible absorption nutrient substance and vitaminic enteral film by activating immune system.Although this disease can be diagnosed out at any age, obtain diagnosis among the child of introducing corn in its ablactation back diet of being everlasting.Symptom can be very trickle, and the patient can feel well with not having reason within a certain period of time before making diagnosis.

It is painful that initial symptoms generally includes become easy irriate and sensation, follows to be off one's feed and can't to increase weight.Stool (defecation) can become unable, loose and unpleasant.Some children begin vomiting and diarrhoea, so the error diagnosis of " gastroenteritis " is made to it by regular meeting.Stomach can be swollen, and the wasting of arm and lower limb and attenuating.In the adult, symptom may be similarly, comprises the constipation and the abdominal distention of lose weight, seriously suffer from diarrhoea or follow " aerofluxus " of following pale complexion.There is half adult can not have any symptom from intestinal portion with celiac disease.Its regular meeting because following reason go to see the doctor: tired out, psychological problems extremely, as depressed, osteodynia and even be fracture (because bone attenuate due to), oral ulcer or foaming sometimes, mainly appear at the itching property erythra (being called dermatitis herpetiformis) of ancon and knee.

Some women that suffer from celiac disease are difficult to pregnancy, and can therefore obtain diagnosis.Recurrent abortion (naturality miscarriage) is relevant with celiac disease sometimes.Some women obtain diagnosis at phenolics, because its intestinal portion can't absorb enough ferrum and vitamin satisfies pregnant needs, thereby make its serious anemia.Baby's the frequency that the mother who suffers from celiac disease gives birth to the intrauterine age little (intrauterine growthing lag) is higher.

If without treatment, then celiac disease can cause anemia, osteopathia and can cause the cancer of some form under less situation.Present most important treatment is to avoid all to contain the food of seitan.This common result is that the enteral membrane damage is improved or even disappearance.Yet, can cause damage again if in diet, introduce seitan again.

Although celiac disease can not prevent, the diet of adhering to not containing seitan can reverse the damage of small intestinal.This needs suitable self-discipline.Need find a kind of following medicine: can make the edible for patients normal diet and can avoid mineral and vitamin shortage and other disease relevant with celiac disease with low-risk side effect.

Ceylon sore mouth is a kind of torrid zone and semi-tropical digestive problems of appearing at.The people that suffer from ceylon sore mouth can not absorb nutrient substance, especially Vitamin B12 and folic acid well.Diarrhoea is the cardinal symptom of ceylon sore mouth; The people of edible significant quantities of fat food can eat the more serious diarrhoea of people's experience of low fat diet.Other symptom comprises abdominal colic, feels sick, loss of weight, aerofluxus and dyspepsia.

Approximately just there is 1 people influenced by ceylon sore mouth in per 1000000 populations and appears at approximately 30 ° of equator north latitude between 30 ° in the equator south latitude.It is more common in some country, comprises India, Haiti, Cuba, Puerto Rico and the Dominica Republica.Its in Africa, Bahamas Islands and Jamaica are uncommon or do not exist.This disease brings misery for the resident and the visitor of influenced country, but it can influence the visitor of stop 6 months or longer time usually.

People do not determine the reason of ceylon sore mouth as yet, but it is likely because of due to the combination of various factors, and this factor comprises and infecting and malnutrition that it can cause damage to the small intestinal inner membrance together, thereby makes the small intestinal inner membrance can't absorb nutrient substance.

The diagnosis meeting of ceylon sore mouth is very complicated, is because many diseases all have similar symptom.Implement stool and blood testing to get rid of other diarrhoea reason.If these tests are negative and the patient once lived in the torrid zone for a long time, then ceylon sore mouth may be the reason that causes this disease.Thereby can implement biopsy and identify the typical planarization of intestinal villi to check fine hair.

Some blood testing also can help the diagnosis of ceylon sore mouth.Because this disease can be blocked the absorption of some vitamin and mineral, so can observe albumin, calcium or vitamin D, A, K and the E of low content.The patient also can anemia occur because of Vitamin B12 and folic acid deficiency.In addition, the stool sample can represent excess fats.

Treatment can be 3 to 6 months antibiotic and folic acid (folic acid or folate) fill-in usually.The people who lacks Vitamin B12 also can accept the vitamin fill-in.

Summary of the invention

But one aspect of the present invention is the antibody of specific bond MAdCAM is used for the treatment of purposes in the medicine of celiac disease and/or ceylon sore mouth in preparation.Another aspect of the present invention is a kind of anti-MAdCAM antibody treatment celiac disease of treatment effective dose and/or method of ceylon sore mouth (preferably celiac disease) used.

Another aspect of the present invention is anti--α ₄β ₇Alpha 2 integrin antibodies is used for the treatment of purposes in the medicine of celiac disease and/or ceylon sore mouth (preferably celiac disease) in preparation.Preferably, this anti--α ₄β ₇Alpha 2 integrin antibodies is humanization Act-1, is also referred to as MLN02.Another aspect of the present invention is to use the anti--α of treatment effective dose ₄β ₇The method of antibody (preferably MLN02) treatment celiac disease and/or ceylon sore mouth (preferably celiac disease).

Another aspect of the present invention is MAdCAM-α ₄β ₇6 integrin-mediated adherent inhibitor is used for the treatment of purposes in the medicine of celiac disease and/or ceylon sore mouth in preparation.Another aspect of the present invention is to use the MAdCAM-α of treatment effective dose ₄β ₇The 6 integrin-mediated adherent inhibitor for treating celiac disease and/or the method for ceylon sore mouth.

Preferably, but be used for anti-MAdCAM antibody of the present invention or its antigen-binding portion thereof specific bond MAdCAM.More preferably, the CDR sequence of this antibody is the antigen-binding portion thereof of people CDR sequence or people's antibody at least.Preferably, this antibody be people's antibody, further preferably human monoclonal antibodies or its antigen-binding portion thereof, be more preferably the antibody or its antigen-binding portion thereof that can be used as the MAdCAM antagonist.

Preferably, an antibody or a part have at least a following character:

(a) in conjunction with people's cell;

(b) MAdCAM had selectivity than at least 100 times of VCAM or fibronectin height;

(c) with 3 * 10 ^-10M or lower K _dIn conjunction with people MAdCAM; Or

(d) suppress α ₄β ₇Express cell is to the combination of people MAdCAM,

(e) suppressing lymphocyte raises to gastrointestinal is adenoid.

Preferably, antibody or antigen-binding portion thereof can suppress people MAdCAM to α ₄β ₇Combination, and have at least a following character:

(a) with reference to the antibody cross competition combine MAdCAM;

(b) with reference to antibody competition combine MAdCAM;

(c) with reference to the identical MAdCAM epi-position of antibodies;

(d) with the K identical substantially with reference antibody _dIn conjunction with MAdCAM;

(e) with the dissociation rate substantially identical with reference antibody in conjunction with MAdCAM;

Wherein should be selected from: monoclonal antibody 1.7.2 with reference to antibody, monoclonal antibody 1.8.2, monoclonal antibody 6.14.2, monoclonal antibody 6.22.2, monoclonal antibody 6.34.2, monoclonal antibody 6.67.1, monoclonal antibody 6.73.2, monoclonal antibody 6.77.1, monoclonal antibody 7.16.6, monoclonal antibody 7.20.5, monoclonal antibody 7.26.4, monoclonal antibody 9.8.2, monoclonal antibody 6.22.2-mod, monoclonal antibody 6.34.2-mod, monoclonal antibody 6.67.1-mod, monoclonal antibody 6.77.1-mod and monoclonal antibody 7.26.4-mod.

In another aspect of this invention, the variable region of heavy chain of this anti-MAdCAM antibody, variable region of light chain or the two have at least 90% homogeneity with the corresponding region that is selected from following monoclonal antibody on aminoacid sequence, this monoclonal antibody is selected from: monoclonal antibody 1.7.2, monoclonal antibody 1.8.2, monoclonal antibody 6.14.2, monoclonal antibody 6.22.2, monoclonal antibody 6.34.2, monoclonal antibody 6.67.1, monoclonal antibody 6.73.2, monoclonal antibody 6.77.1, monoclonal antibody 7.16.6, monoclonal antibody 7.20.5, monoclonal antibody 7.26.4, monoclonal antibody 9.8.2, monoclonal antibody 6.22.2-mod, monoclonal antibody 6.34.2-mod, monoclonal antibody 6.67.1-mod, monoclonal antibody 6.77.1-mod and monoclonal antibody 7.26.4-mod.

Preferably, this antibody is selected from:

(a) contain aminoacid sequence that is shown in SEQ ID NO:2 and SEQ ID NO:4 and the antibody that does not contain signal sequence;

(b) contain aminoacid sequence that is shown in SEQ ID NO:6 and SEQ ID NO:8 and the antibody that does not contain signal sequence;

(c) contain aminoacid sequence that is shown in SEQ ID NO:10 and SEQ ID NO:12 and the antibody that does not contain signal sequence;

(d) contain aminoacid sequence that is shown in SEQ ID NO:14 and SEQ ID NO:16 and the antibody that does not contain signal sequence;

(e) contain aminoacid sequence that is shown in SEQ ID NO:18 and SEQ ID NO:20 and the antibody that does not contain signal sequence;

(f) contain aminoacid sequence that is shown in SEQ ID NO:22 and SEQ ID NO:24 and the antibody that does not contain signal sequence;

(g) contain aminoacid sequence that is shown in SEQ ID NO:26 and SEQ ID NO:28 and the antibody that does not contain signal sequence;

(h) contain aminoacid sequence that is shown in SEQ ID NO:30 and SEQ ID NO:32 and the antibody that does not contain signal sequence;

(i) contain aminoacid sequence that is shown in SEQ ID NO:34 and SEQ ID NO:36 and the antibody that does not contain signal sequence;

(j) contain aminoacid sequence that is shown in SEQ ID NO:38 and SEQ ID NO:40 and the antibody that does not contain signal sequence;

(k) contain aminoacid sequence that is shown in SEQ ID NO:42 and SEQ ID NO:44 and the antibody that does not contain signal sequence;

(l) contain aminoacid sequence that is shown in SEQ ID NO:46 and SEQ ID NO:48 and the antibody that does not contain signal sequence;

(m) contain aminoacid sequence that is shown in SEQ ID NO:52 and SEQ ID NO:54 and the antibody that does not contain signal sequence;

(n) contain aminoacid sequence that is shown in SEQ ID NO:56 and SEQ ID NO:58 and the antibody that does not contain signal sequence;

(o) contain aminoacid sequence that is shown in SEQ ID NO:60 and SEQ ID NO:62 and the antibody that does not contain signal sequence;

(p) contain aminoacid sequence that is shown in SEQ ID NO:64 and SEQ ID NO:66 and the antibody that does not contain signal sequence; And

(q) contain aminoacid sequence that is shown in SEQ ID NO:42 and SEQ ID NO:68 and the antibody that does not contain signal sequence.

In another aspect of this invention, this monoclonal antibody or one antigen-binding portion thereof are selected from following antibody:

(a) heavy chain comprises with reference to heavy chain CDR1, the CDR2 of antibody and the aminoacid sequence of CDR3, and this is selected from reference to antibody: 1.7.2,1.8.2,6.14.2,6.22.2,6.34.2,6.67.1,6.73.2,6.77.1,7.16.6,7.20.5,7.26.4,9.8.2,6.22.2-mod, 6.34.2-mod, 6.67.1-mod, 6.77.1-mod and 7.26.4-mod

(b) light chain comprises with reference to light chain CDR1, the CDR2 of antibody and the aminoacid sequence of CDR3, and this is selected from reference to antibody: 1.7.2,1.8.2,6.14.2,6.22.2,6.34.2,6.67.1,6.73.2,6.77.1,7.16.6,7.20.5,7.26.4,9.8.2,6.22.2-mod, 6.34.2-mod, 6.67.1-mod, 6.77.1-mod and 7.26.4-mod

(c) this antibody comprises the heavy chain of (a) and light chain (b); And

(d) antibody of this (c), wherein this heavy chain and light chain cdr amino acid sequence are selected from identical with reference to antibody.

In another aspect of this invention, this monoclonal antibody or antigen-binding portion thereof comprise:

(a) contain the heavy chain of following antibody heavy chain variable region aminoacid sequence, described antibody is selected from: 1.7.2 (SEQ ID NO:2); (1.8.2 SEQ ID NO:6); (6.14.2 SEQ ID NO:10); (6.22.2 SEQ ID NO:14); (6.34.2 SEQ ID NO:18); (6.67.1 SEQ IDNO:22); (6.73.2 SEQ ID NO:26); (6.77.1 SEQ ID NO:30); (7.16.6 SEQID NO:34); (7.20.5 SEQ ID NO:38); (7.26.4 SEQ ID NO:42); And 9.8.2 (SEQ ID NO:46); (6.22.2-mod SEQ ID NO:52); (6.34.2-mod SEQID NO:56); (6.67.1-mod SEQ ID NO:60); (6.77.1-mod SEQ ID NO:64); And 7.26.4-mod (SEQ ID NO:42);

(b) contain the light chain of following antibody chain variable region aminoacid sequence, described antibody is selected from: 1.7.2 (SEQ ID NO:4); (1.8.2 SEQ ID NO:8); (6.14.2 SEQ ID NO:12); (6.22.2 SEQ ID NO:16); (6.34.2 SEQ ID NO:20); (6.67.1 SEQ IDNO:24); (6.73.2 SEQ ID NO:28); (6.77.1 SEQ ID NO:32); (7.16.6 SEQID NO:36); (7.20.5 SEQ ID NO:40); (7.26.4 SEQ ID NO:44); And 9.8.2 (SEQ ID NO:48); (6.22.2-mod SEQ ID NO:54); (6.34.2-mod SEQID NO:58); (6.67.1-mod SEQ ID NO:62), 6.77.1-mod (SEQ ID NO:66); And 7.26.4-mod (SEQ ID NO:68); Or

(c) heavy chain (a) and light chain (b).

Another aspect of the present invention is heavy chain and/or light chain or its variable region or the nucleic acid molecules of other antigen-binding portion thereof or the aforementioned arbitrary molecule of encoding and the purposes of pharmaceutically acceptable carrier of this anti-MAdCAM antibody.This respect of the present invention comprises that the fragment of arbitrary above-mentioned antibody (includes but not limited to Fab fragment, F (ab ') ₂Fragment, strand Fv (scFv) fragment) purposes.

Preferably, this anti-MAdCAM antibody is the human inhibitory anti-MAdCAM antibody that is selected from 1.7.2,1.8.2,6.14.2,6.22.2,6.34.2,6.67.1,6.73.2,6.77.1,7.16.6,7.20.5,7.26.4,9.8.2,6.22.2-mod, 6.34.2-mod, 6.67.1-mod, 6.77.1-mod or 7.26.4-mod described in WO 2005/067620.Preferably, this anti-MAdCAM antibody comprises following light chain, this light chain contain be selected from as shown in WO2005/067620 SEQ ID NO:4,8,12,16,20,24,28,32,36,40,44,48,54,58,62,66 or 68 aminoacid sequence (containing or do not contain signal sequence) or as described in the aminoacid sequence any the variable region or one or more from as described in the CDR of aminoacid sequence.This anti-MAdCAM antibody preferably comprises following heavy chain, this heavy chain contain be selected from as shown in WO2005/067620 SEQ ID NO:2,6,10,14,18,22,26,30,34,38,42,46,52,56,60 or 64 aminoacid sequence (containing or do not contain signal sequence) or variable region amino acid sequence or one or more from as described in the cdr amino acid sequence of aminoacid sequence.This anti-MAdCAM antibody preferably contains in above-mentioned sequence the people anti-MAdCAM antibody of the CDR1 initiating terminal of any to CDR 3 terminal amino acids sequence.Be used for anti-MAdCAM antibody of the present invention and also contain any anti-MAdCAM antibody in one or more FR district of above-mentioned sequence.

Be used for anti-MAdCAM antibody of the present invention and also can comprise one the anti-MAdCAM antibody that contains the above-mentioned aminoacid sequence that wherein carries out one or more modifications.For example, having chemically reactive cysteine in this antibody can be replaced by another residue (including but not limited to alanine or serine).This replacement can occur in atypia cysteine place or typical cysteine place.This replacement can be carried out in the CDR in antibody variable territory or framework region or constant domain.

Also can carry out aminoacid replacement to eliminate potential Proteolytic enzyme site in the antibody.Such site can be present in the CDR or framework region or constant domain in antibody variable territory.The removal in the replacement of cysteine residues and Proteolytic enzyme site can reduce the heterogeneity in the antibody product.Agedoite-the glycine that can form potential deacylated tRNA amine site is to eliminating by changing in two kinds of residues one or both.Carry out adding or removal that aminoacid replacement can be used for the potential glycosylation site in the variable region of antibody of the present invention.

Cleavable falls to be used for the terminal lysine of C-of the heavy chain of anti-MAdCAM antibody of the present invention.The heavy chain of anti-MAdCAM antibody and light chain can comprise signal sequence according to circumstances.

Be used for 12 preferred inhibition people anti-MAdCAM monoclonal antibodies of the present invention (1.7.2,1.8.2,6.14.2,6.22.2,6.34.2,6.67.1,6.73.2,6.77.1,7.16.6,7.20.5,7.26.4 and 9.8.2) and be specified in WO 2005/067620 (it is introduced in the patent specification with way of reference in full).

The specific embodiment

The classification of anti-MAdCAM antibody and subclass

This antibody can be IgG, IgM, IgE, IgA or IgD molecule.Preferably, this antibody belongs to the IgG class and belongs to IgG ₁, 1gG ₂, 1gG ₃Or 1gG ₄Subclass.More preferably, this anti-MAdCAM antibody is 1gG ₂Or 1gG ₄Subclass.More preferably, this anti-MAdCAM antibody with as 1gG ₂Antibody 1.7.2,1.8.2,7.16.6,7.20.5,7.26.4,6.22.2-mod, 6.34.2-mod, 6.67.1-mod, 6.77.1-mod or 7.2 6.4-mod or with as 1gG ₄6.14.2,6.22.2,6.34.2,6.67.1,6.73.2,6.77.1 or 9.8.2 (described in WO 2005/067620) belong to identical category and subclass.

Classification and subclass can be determined by arbitrary known method in the industry under the anti-MAdCAM antibody.Generally speaking, the classification of antibody and subclass can use and particular category and subclass antibody are had specific antibody determine.The commercially available acquisition of such antibody.ELISA, Western engram analysis and other technology all can be determined this classification and subclass.Perhaps, this classification and subclass can followingly be determined: measure all of antibody or the sequence of a part of heavy chain and/or light chain constant domain; The known amino acid sequence of its aminoacid sequence and various classification and subclass immunoglobulin is compared; And the classification and the subclass of this antibody be defined as showing the conforming classification of highest serial.

Option of species and molecular selectivity

Being used for anti-MAdCAM antibody of the present invention had both shown option of species and had also shown molecular selectivity.This anti-MAdCAM antibody can be in conjunction with the MAdCAM of people, macaque or Canis familiaris L..Other the anti-MAdCAM antibody of the present invention that is used for can not be in conjunction with such as New World monkey species such as Adeps seu carnis Rhiopithecus roxellanae.People can use well-known process in the industry to determine the option of species of anti-MAdCAM antibody.For example, people can use Western engram analysis, FACS, ELISA or immunohistochemistry to determine option of species.In a preferred embodiment, people can use immunohistochemistry to determine option of species.

But the anti-MAdCAM antibody that is used for specific bond MAdCAM of the present invention is higher than VCAM, fibronectin or any other antigen to the selectivity of MAdCAM, and it exceeds at least 10 times, is preferably up to few 20,30,40,50,60,70,80 or 90 times, most preferably high at least 100 times.Preferably, this anti-MAdCAM antibody is not except that to representing any tangible combination to VCAM, fibronectin or any other antigen the MAdCAM.People can use in the industry well-known process to determine the selectivity of anti-MAdCAM antibody to MAdCAM according to the instruction of this description.For example, people can use Western engram analysis, FACS, ELISA or immunohistochemistry to determine this selectivity.

Anti-MAdCAM antibody is in conjunction with the MAdCAM affinity

Being used for anti-MAdCAM antibody of the present invention preferably can be with high-affinity specifically in conjunction with MAdCAM.Be used for anti-MAdCAM antibody of the present invention with 3 * 10 ^-8M or lower K _dSpecifically in conjunction with MAdCAM, as measured by surface plasma resonance (such as BIAcore).Preferably, antibody is with 1 * 10 ^-8Or lower or 1 * 10 ^-9M or lower Kd are specifically in conjunction with MAdCAM.More preferably, antibody is with 1 * 10 ^-10M or lower K _dSpecifically in conjunction with MAdCAM.Be used for antibody of the present invention with 2.66 * 10 ^-10M or lower, 2.35 * 10 ^-11M or lower or 9 * 10 ^-12M or lower K _dSpecifically in conjunction with MAdCAM.Preferably, this antibody is with 1 * 10 ^-11M or lower K _dSpecifically in conjunction with MAdCAM.Preferably, this antibody is with the K identical substantially with the antibody that is selected from 1.7.2,1.8.2,6.14.2,6.22.2,6.34.2,6.67.1,6.73.2,6.77.1,7.16.6,7.20.5,7.26.4,9.8.2,6.22.2-mod, 6.34.2-mod, 6.67.1-mod, 6.77.1-mod or 7.26.4-mod described in WO 2005/067620 _dSpecifically in conjunction with MAdCAM.

Has " the identical K of cardinal principle with reference antibody _d" antibody have be ± 100pM, preferably ± 50pM, be more preferably ± 20pM, further preferably ± 10pM, ± 5pM or ± K of 2pM _d(in identical experiment with the K of reference antibody _dCompare).Preferably, this antibody is with the K identical substantially with the antibody that contains one or more following variable domains or one or more following CDR _dIn conjunction with MAdCAM, this variable domains or CDR are from being selected from following antibody: the 1.7.2 described in WO2005/067620,1.8.2,6.14.2,6.22.2,6.34.2,6.67.1,6.73.2,6.77.1,7.16.6,7.20.5,7.26.4,9.8.2,6.22.2-mod, 6.34.2-mod, 6.6 7.1-mod, 6.77.1-mod or 7.26.4-mod.Preferably, this antibody is with the K identical substantially with the antibody that contains following aminoacid sequence or its variable domains _dIn conjunction with MAdCAM, it is one of following that this aminoacid sequence is selected from: the SEQID NO:2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32,34,36,38,40,42,44,46,48,52,54,56,58,62,64 described in WO2005/067620,66 or 68 (containing or do not contain signal sequence).Preferably, this antibody is with the K identical substantially with the antibody that contains one or more following CDR _dIn conjunction with MAdCAM, this CDR is from containing the antibody that is selected from following aminoacid sequence: the SEQ ID NO:2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32,34,36,38,40,42,44,46,48,52,54,56,58,62,64,66 or 68 described in WO 2005/067620.

Anti-MAdCAM antibody can be determined by arbitrary known method in the industry the binding affinity of MAdCAM.In one embodiment, this binding affinity can pass through competitive ELISA, RIA or surface plasma resonance (such as BIAcore) measurement.At one more in the preferred embodiment, this binding affinity is to measure by surface plasma resonance.In a further preferred embodiment, this binding affinity and dissociation rate are to use BIAcore to measure.The example of determining binding affinity can be referring to WO 2005/067620.

The half-life of anti-MAdCAM antibody

Be used for the half-life that anti-MAdCAM antibody of the present invention had 1 day at least in vitro or in vivo.Preferably, this antibody or its part have at least 3 days half-life.More preferably, this antibody or its part had 4 days or the longer half-life.Further preferably, this antibody or its part had 8 days or the longer half-life.Being used for antibody of the present invention or its antigen-binding portion thereof also can be through deriving or modifies so that it has the longer half-life, such as hereinafter argumentation.In another preferred embodiment, this antibody can contain point mutation to increase serum half-life, described in WO 00/09560.

Can measure antibody half life by the known any way of those skilled in the art.For example, can in one section suitable time, measure by Western engram analysis, ELISA or RIA antibody half life.Antibody half life can be any such as suitable animals such as primates (for example macaque, monkey or people) in-vivo measurement.

The evaluation of the MAdCAM epi-position of anti-MAdCAM antibody identification

The present invention also provides the purposes that people's anti-MAdCAM antibody of same antigen or epi-position is provided with people's anti-MAdCAM antibody of providing in this patent.In addition, the invention provides purposes with people's anti-MAdCAM antibody of people's anti-MAdCAM antibody competition or cross competition.Preferably, this people's anti-MAdCAM antibody is 1.7.2,1.8.2,6.14.2,6.22.2,6.34.2,6.67.1,6.73.2,6.77.1,7.16.6,7.20.5,7.26.4,9.8.2,6.22.2-mod, 6.34.2-mod, 6.67.1-mod, 6.77.1-mod or the 7.26.4-mod that discloses among the WO 2005/067620.Preferably, this people's anti-MAdCAM antibody contains from the one or more variable domains that are selected from following antibody or one or more CDR:1.7.2,1.8.2,6.14.2,6.22.2,6.34.2,6.67.1,6.73.2,6.77.1,7.16.6,7.20.5,7.26.4,9.8.2,6.22.2-mod, 6.34.2-mod, 6.67.1-mod, 6.77.1-mod or 7.26.4-mod.Preferably, this people's anti-MAdCAM antibody contains in of being selected from the aminoacid sequence of (containing or do not contain signal sequence) of SEQ ID NO:2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32,34,36,38,40,42,44,46,48,52,54,56,58,62,64,66 or 68 among the WO 2005/067620 or its variable domains one.Preferably, this people's anti-MAdCAM antibody contains one or more CDR from one antibody in the SEQ ID NO:2 that is selected from WO 2005/067620,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32,34,36,38,40,42,44,46,48,52,54,56,58,62,64,66 or 68 the aminoacid sequence.

People can use various known methods in the industry to determine whether anti-MAdCAM antibody combines same antigen with another anti-MAdCAM antibody.Whether for example, people can utilize known anti-MAdCAM antibody capture antigen, with antigen under the eluting on this anti-MAdCAM antibody, and measure test antibody subsequently can be in conjunction with the antigen through eluting.Whether people can compete with another anti-MAdCAM antibody by following definite antibody: this anti-MAdCAM antibody is bonded on the MAdCAM under saturation conditions, and surveys the ability of measuring examination antibodies MAdCAM subsequently.If test antibody can combine MAdCAM simultaneously with anti-MAdCAM antibody, then this test antibody can be in conjunction with the epi-position that is different from anti-MAdCAM antibody.Yet if this antibody can not be simultaneously in conjunction with MAdCAM, this test antibody can be at war with this people's anti-MAdCAM antibody.This experiment can be used ELISA or surface plasma resonance or be preferably BIAcore and implement.For the test anti-MAdCAM antibody whether with another anti-MAdCAM antibody cross competition, people can the above-mentioned competing method of two-way use, determines promptly whether known antibodies blocks test antibody, otherwise and determines whether test antibody blocks known antibodies.

Hydroxyl chain and heavy chain gene use

The present invention also provides the purposes of the anti-MAdCAM antibody that comprises the variable region of light chain of being encoded by people's kappa gene.Preferably, this variable region of light chain is by people V κ A2, A3, A26, B3, O12 or O18 gene family coding.Preferably, to contain with respect to kind be that the aminoacid replacement of people V κ A2, A3, A26, B3, O12 or O18 sequence is no more than 11, is no more than 6 or be no more than 3 to this light chain.Preferably, described aminoacid replacement is that conservative replaces.

Preferably, the VL of anti-MAdCAM antibody contain with the VL of antibody 1.7.2, the 1.8.2 described in the WO 2005/067620,6.14.2,6.22.2,6.34.2,6.67.1,6.73.2,6.77.1,7.16.6,7.20.5,7.26.4,9.8.2,6.2 2.2-mod, 6.34.2-mod, 6.67.1-mod, 6.77.1-mod or 7.26.4-mod any or a plurality of identical compared to kind being the sudden change of (germline) aminoacid sequence.The present invention includes the purposes that adopts the anti-MAdCAM antibody of identical people V κ and people J kappa gene with illustration antibody.This antibody can contain one or more identical sudden changes compared to kind of system with one or more illustrated antibody, or this antibody lists the identical position of antibody and can comprise different replacements one or more and one or more.For example, the VL of this anti-MAdCAM antibody can comprise these identical aminoacid replacement and another aminoacid replacement identical with antibody 7.26.4 that exists among one or more and the antibody 7.16.6.In this way, the people's different characteristic that can mix and mate antibodies is to change (for example) antibody to the affinity of MAdCAM or it is from antigenic dissociation rate.Can with any or a plurality of VL that are present in antibody 1.7.2,1.8.2,6.14.2,6.22.2,6.34.2,6.67.1,6.73.2,6.77.1,7.16.6,7.20.5,7.26.4,9.8.2,6.22.2-mod, 6.34.2-mod, 6.67.1-mod, 6.77.1-mod or 7.26.4-mod in the same position place suddenly change, but conserved amino acid replaces and does not carry out with same amino acid.For example, if the aminoacid replacement compared to kind of system among one of antibody 1.7.2,1.8.2,6.14.2,6.2 2.2,6.34.2,6.67.1,6.73.2,6.77.1,7.16.6,7.20.5,7.26.4,9.8.2,6.22.2-mod, 6.34.2-mod, 6.67.1-mod, 6.77.1-mod or 7.26.4-mod is a glutamic acid, but then people's conservative replaces aspartic acid.Similarly, if aminoacid replacement is a serine, but then people's conservative replaces threonine.

The light chain of anti-MAdCAM antibody can contain the aminoacid sequence identical with the VL aminoacid sequence of 1.7.2,1.8.2,6.14.2,6.22.2,6.34.2,6.67.1,6.73.2,6.77.1,7.16.6,7.20.5,7.26.4,9.8.2,6.22.2-mod, 6.34.2-mod, 6.67.1-mod, 6.77.1-mod or 7.26.4-mod.This light chain preferably contains the identical aminoacid sequence in light chain CDR district with 1.7.2,1.8.2,6.14.2,6.22.2,6.34.2,6.67.1,6.73.2,6.77.1,7.16.6,7.20.5,7.26.4,9.8.2,6.22.2-mod, 6.34.2-mod, 6.67.1-mod, 6.77.1-mod or 7.26.4-mod.This light chain can contain the aminoacid sequence in the light chain CDR district with at least one 1.7.2,1.8.2,6.14.2,6.22.2,6.34.2,6.67.1,6.73.2,6.77.1,7.16.6,7.20.5,7.26.4,9.8.2,6.22.2-mod, 6.34.2-mod, 6.67.1-mod, 6.77.1-mod or 7.26.4-mod.This light chain can contain the aminoacid sequence that has from the CDR of the different light chains that use identical V κ and J kappa gene.Preferably, the CDR from different light chains derives from 1.7.2,1.8.2,6.14.2,6.22.2,6.34.2,6.67.1,6.73.2,6.77.1,7.16.6,7.20.5,7.26.4,9.8.2,6.22.2-mod, 6.34.2-mod, 6.67.1-mod, 6.77.1-mod or 7.26.4-mod.Preferably, this light chain contains the aminoacid sequence of the SEQ ID NO:4,8,12,16,20,24,28,32,36,40,44,48,54,58,62,64,66 or 68 (containing or do not contain signal sequence) that is selected from WO 2005/067620.Preferably, this light chain contains the nucleotide sequence coded aminoacid sequence that is wherein had the aminoacid sequence of 1 to 11 amino acid whose insertion, disappearance or replacement by the nucleotide sequence of the SEQ ID NO:3,7,11,15,19,23,27,31,35,39,43,47,53,57,61,65 or 67 that is selected from WO 2005/067620 (containing or do not contain signal sequence) or coding.Preferably, this aminoacid replacement is that conserved amino acid replaces.This antibody or its part can contain lambda light chain.

The present invention also provides and comprises people VH gene order or be derived from the anti-MAdCAM antibody of sequence of people VH gene or the purposes of its part.This heavy chain amino acid sequence can be derived from people VH 1-18,3-15,3-21,3-23,3-30,3-33 or 4-4 gene family.Preferably, be people VH 1-18,3-15,3-21,3-23,3-30,3-33 or 4-4 gene order with respect to kind, this heavy chain contains and is no more than 15, is no more than 6 or be no more than 3 amino acid changes.

The SEQ ID NO:2,6,10,14,18,22,26,30,34,38,42 and 46 that is disclosed in WO 2005/067620 provides the aminoacid sequence of the total length heavy chain that is used for 12 anti-MAdCAM antibodies of the present invention.All related SEQ ID No of this description are meant the sequence among the actual WO2005/067620 of being disclosed in.

Preferably, among the VH of the VH of this anti-MAdCAM antibody and antibody 1.7.2,1.8.2,6.14.2,6.22.2,6.34.2,6.73.2,6.77.1,7.16.6,7.20.5,7.26.4,9.8.2,6.22.2-mod, 6.34.2-mod, 6.67.1-mod, 6.77.1-mod or 7.26.4-mod any or a plurality of to contain identical be the sudden change of aminoacid sequence compared to kind.With mentioned above similar, this antibody contains one or more identical sudden changes compared to kind of system with one or more illustrated antibody.This antibody can also contain different replacements in the one or more positions identical with one or more illustrated antibody.For example, the VH of this anti-MAdCAM antibody can contain the identical aminoacid replacement of existing aminoacid among one or more and the antibody 7.16.6, and the other aminoacid replacement identical with antibody 7.26.4.Mode according to this, the different characteristic that people can mix and mate antibodies is to change (for example) antibody to the affinity of MAdCAM or it is from antigenic dissociation rate.Can carry out with being present in compared to the aminoacid replacement of kind of system with reference to the identical position of the replacement among any or a plurality of VH among antibody 1.7.2,1.8.2,6.14.2,6.2 2.2,6.3 4.2,6.67.1,6.77.1,7.16.6,7.20.5,7.2 6.4,9.8.2,6.22.2-mod, 6.34.2-mod, 6.67.1-mod, 6.77.1-mod or the 7.26.4-mod compared to kind of system, but this position can replace with different residue, and Here it is compared to the conservative replacement of reference antibody.

Preferably, the heavy chain that is used for anti-MAdCAM antibody of the present invention contains the identical aminoacid sequence of aminoacid sequence with the VH of 1.7.2,1.8.2,6.14.2,6.22.2,6.34.2,6.67.1,6.73.2,6.77.1,7.16.6,7.20.5,7.26.4,9.8.2,6.22.2-mod, 6.34.2-mod, 6.67.1-mod, 6.77.1-mod or 7.26.4-mod.More preferably, this heavy chain contains the identical aminoacid sequence in heavy chain CDR district with 1.7.2,1.8.2,6.14.2,6.2 2.2,6.34.2,6.67.1,6.73.2,6.77.1,7.16.6,7.20.5,7.26.4,9.8.2,6.22.2-mod, 6.34.2-mod, 6.67.1-mod, 6.77.1-mod or 7.26.4-mod.Preferably, this heavy chain contains the aminoacid sequence from least one CDR district of the heavy chain of 1.7.2,1.8.2,6.14.2,6.22.2,6.34.2,6.67.1,6.73.2,6.77.1,7.16.6,7.20.4,7.26.4,9.8.2,6.22.2-mod, 6.34.2-mod, 6.67.1-mod, 6.77.1-mod or 7.26.4-mod, or this heavy chain can contain the aminoacid sequence that has from the CDR of different heavy chains.Preferably, should derive from 1.7.2,1.8.2,6.14.2,6.22.2,6.34.2,6.67.1,6.73.2,6.77.1,7.16.6,7.20.5,7.26.4,9.8.2,6.22.2-mod, 6.34.2-mod, 6.67.1-mod, 6.77.1-mod or 7.26.4-mod from the CDR of different heavy chains.Preferably, this heavy chain contains the SEQ ID NO:2 that is selected from WO 2005/067620,6,10,14,18,22,26,30,34,38,42,46,52,56,60 or 64 aminoacid sequence (containing or do not contain signal sequence).This heavy chain can also contain the nucleotide sequence coded aminoacid sequence that is wherein had the aminoacid sequence of 1 to 15 amino acid whose insertion, disappearance or replacement by the SEQ ID NO:1 that is selected from WO2005/067620,5,9,13,17,21,25,29,33,37,41,45,51,55,59 or 63 nucleotide sequence or coding.This replaces preferably, and conserved amino acid replaces.

Be used to prepare nucleic acid, carrier, host cell and the recombination method of antibody

The nucleic acid, carrier, host cell and the recombination method that are used for preparing these antibody are set forth in WO2005/067620.

Through deriving and the antibody of labelling

The part of antibody of the present invention or antibody can be derived or is connected to another molecule (for example, another peptide or protein).Generally speaking, this antibody or its each several part can make MAdCAM in conjunction with not derived or the harmful effect of labelling through deriving.Therefore, be used for antibody of the present invention and antibody moiety be intended to comprise the complete form of the described people's anti-MAdCAM antibody of this description and modified form these two.For example, be used for antibody of the present invention or antibody moiety and on function, can connect (by chemical coupling, gene fusion, non-covalent bond association or alternate manner) to one or more other molecular entities, for example another antibody (for example, bi-specific antibody or double antibody), detection agent, cytotoxic agent, medical agent and/or can mediate this antibody or the protein or the peptide (for example Succ-PEG-DSPE core space or polyhistidyl label) of an antibody part and another molecular association.

Can pass through crosslinked two or more antibody (of the same type or dissimilar, for example, to generate bi-specific antibody) a kind of deutero-antibody of preparation.Suitable cross-linking agent (for example comprises these heterobifunctional agents with two different reactive groups separating by suitable introns; between-maleimide benzoyl-N-hydroxysuccinimide eater) or homobifunctional agent (for example, disuccinimidyl suberate).These cross-linking agent can be from Pierce Chemical company, Rockford, and III buys.

The antibody of deriving of another kind of type is the antibody of labelling.The useful detection agent of antibody of the present invention or antibody moiety of being used to derive comprises fluorescent chemicals, comprises fluorescein, Fluorescein isothiocyanate, rhodamine, 5-dimethyl amine-1-naphthalene sulfonyl chloride, rhodophyll, lanthanide series phosphor etc.Antibody also can be with the enzyme labelling that can be used for detecting, for example horseradish peroxidase, beta galactosidase, luciferase, alkali phosphatase, glucoseoxidase and like that.When with detectable enzymic-labelled antibody, but it is can use the additional agents to produce the detection reaction product to detect for this enzyme by adding.For example, when having the reagent horseradish peroxidase, add hydrogen peroxide and diaminobenzidine and can generate the colored reaction product that can detect.Can also be detected with biotin labeling antibody and by indirect measurement avidin or Succ-PEG-DSPE combination.Antibody can be used such as magnetic agent labellings such as gadoliniums.Antibody can also be used the predetermined polypeptide epitope labelling by secondary report (for example, leucine zipper is to sequence, secondary antibody binding site, melts combine domain, epi-position label) identification.In certain embodiments, label is potential sterically hindered to reduce by the introns arm connection of all lengths.

Anti-MAdCAM antibody also can be used through radiolabeled aminoacid labelling.Radioactive label both can be used for diagnostic purpose also can be used for the treatment of purpose.For example, radioactive label can be used for detecting the tissue of expressing MAdCAM by x-ray or other diagnostic techniques.In addition, radioactive label can be used as the tumor treatment that toxin is used for diseased tissue or expression MAdCAM.The example of polypeptide marker thing includes but not limited to following radiosiotope or radionuclide-- ³H, ¹⁴C, ¹⁵N, ³⁵S, ⁹⁰Y, ⁹⁹TC, ¹¹¹In, ¹²⁵I, ¹³¹I.

Anti-MAdCAM antibody can also be derived with chemical group (such as Polyethylene Glycol (PEG), methyl or ethyl or carbohydrate group).These groups can be used for improving the biological characteristics of antibody, for example, increase serum half-life or increase tissue bond.This method also can be applied to the antibody version of any antigen-binding fragment or anti-MAdCAM antibody.

Pharmaceutical composition and cover box

In another aspect, the invention provides the compositions that contains inhibition people anti-MAdCAM antibody and with such combination treatment experimenter's method.In some embodiments, the experimenter of treatment is the people.In other embodiments, this experimenter is the domestic animal experimenters.In certain embodiments, this domestic animal experimenter is Canis familiaris L. or non-human primates.

Treatment can relate to separately or with one or more inhibition anti-MAdCAM monoclonal antibodies of pharmaceutically acceptable carrier combinations administration or its antigen-binding fragment.The inhibition anti-MAdCAM antibody and comprise it compositions can with one or more other treatments, diagnosis or prophylactic action agent administering drug combinations.Extra therapeutic agent comprises antiinflammatory or immunomodulator.These agents include but not limited to external and oral cortical steroid, such as meticortelone (prednisolone), methyl meticortelone, NCX-1015 or budesonide (budesonide); The aminosallcylic acid class is drawn piperazine (mesalazine), Ao Sela piperazine (olsalazine), balsalazide (balsalazide) or NCX-456 such as beauty; The immunomodulator class, such as azathioprine (azathioprine), Ismipur (6-mercaptopurine), methotrexate (methotrexate), cyclosporin (cyclosporin), FK506, IL-10 (Ilodecakin), IL-11 (Oprelevkin), IL-12, MIF/CD 4 antagonisies, CD40 antagonist, such as TNX-100/5-D12, OX40L antagonist, GM-CSF, pimecrolimus (pimecrolimus) or rapamycin (rapamycin); Anti-TNF alpha medicament class is such as infliximab (infliximab), adalimumab (adalimumab), CDP-870, onercept (onercept), Embrel (etanercept); The antiinflammatory class is such as PDE-4 inhibitor (roflumilast (roflumilast) etc.), tace inhibitor (DPC-333, RDP-58 etc.) and ICE inhibitor (VX-740 etc.) and IL-2 receptor antagonist, such as reaching gram force not (daclizumab); Select the adhesion molecule antagonist class, block good fortune (alicaforsen) such as natalizumab (natalizumab), MLN-02 or Ali; The analgesic class, include but not limited to cox 2 inhibitor, such as rofecoxib (rofecoxib), valdecoxib (valdecoxib), celecoxib (celecoxib), P/Q-type voltage sensitivity channel (α 2 δ) regulator, such as gabapentin (gabapentin) and pregabalin (pregabalin), nk 1 receptor antagonist, Cannibinoid receptor modulators and δ opioid receptor agonist; And anti-anything superfluous or useless medicine, antineoplastic agent, angiogenesis inhibitor medicine or chemotherapeutics.Can be included in the identical compositions or separate administration by the agent that this class is extra.

It is like that this description used " pharmaceutically acceptable carrier " means solvent, disperse medium, smears, antibacterial agent and antifungal, isotonic agent and absorption enhancer or absorption delay agent compatible on any and all physiology.The example of pharmaceutically acceptable carrier is water, saline, phosphate buffered saline(PBS), the acetate buffer that contains sodium chloride, glucose, glycerol, Polyethylene Glycol, ethanol and like that and combination.In many cases, preferably with isotonic agent, for example, sugar, polyhydric alcohol (for example, mannitol, sorbitol) or sodium chloride are included in the compositions.Other example of pharmaceutically acceptable material is surfactant, wetting agent or minor amounts of auxiliary substances, and such as moistening or emulsifying agent, preservative agent or buffer agent, it can strengthen antibody storage life or effectiveness.

Being used for compositions of the present invention can take various forms, for example, as liquid, semisolid and solid dosage forms, such as liquid solution (for example, but injectable and infusion solution), dispersion liquid or suspension, lozenge, pill, lyophilized cake, dry powder, liposome and suppository.Preferred form is decided on expectation mode of administration and treatment application.But typical preferred compositions is to be injectable or infusion solution form, for example is similar to the compositions that is used for people's passive immunity.The preference pattern right and wrong of administration are through intestinal (for example, vein, subcutaneous, intraperitoneal, intramuscular, Intradermal) administration.In preferred embodiments, this antibody is by intravenous infusion or drug administration by injection.In a further preferred embodiment, this antibody is by intramuscular, Intradermal or subcutaneous injection administration.When needing, this antibody can pass through pump, enema, suppository or keep somewhere reservoir or administration like that.

Usually, therapeutic combination must be aseptic and stable under production and condition of storage.Said composition can be deployed into the desired structure of solution, lyophilized cake, dry powder, microemulsion, dispersion liquid, liposome or other suitable high drug level.Sterile injectable solution can prepare by following: the anti-MAdCAM antibody of aequum is mixed in the suitable solvent of the combination (depending on the needs) that contains above-mentioned a kind of composition or multiple components, carry out aseptic process subsequently.If for being used to prepare the sterile powder of aseptic parenteral solution, then the preferred for preparation method is vacuum drying and lyophilization, so can before make the powder that active ingredient adds any desired extra composition through the solution of aseptic process from it.Generally speaking, can prepare dispersion liquid by reactive compound being mixed contain in basic disperse medium and the required aseptic mediator that is selected from other composition of cited composition above.The desirable characteristics that for example, can keep solution by surfactant and desired particle size (in the situation of dispersion liquid, passing through surfactant, phospholipid and polymer).By in compositions, mixing the medicament (for example Monostearate, polymeric material, oil and gelatin) that can postpone to absorb the absorption of Injectable composition is prolonged.

Antibody of the present invention can be by the administration of multiple known method in the industry, but for many treatments are used, and preferred route of administering/mode is subcutaneous, intramuscular, Intradermal or intravenous infusion.It is to be appreciated that those skilled in the art that route of administration and/or mode can change because of desired result.

In certain embodiments, can be with this antibody of the preparing carriers that can prevent the antibody rapid release, for example the controlled release modulator comprises implant, percutaneous patch and microencapsulation delivery system.Can use biodegradable biocompatible polymeric, for example vinyl acetic acid vinyl acetate, poly-anhydride, polyglycolic acid, collagen, poe and polylactic acid.Be used to prepare the several different methods power of having patented of this modulator or known by those skilled in the art usually.Referring to, for example, Sustained and Controlled Release Drug Delivery Systems (J.R.Robinson edits, Marcel Dekker company, New York (1978)).

In certain embodiments, but anti-MAdCAM antibody oral administration of the present invention administration for example, maybe can absorb edible carrier administration by inert diluent.Also this chemical compound (and other composition, when needing) can be encapsulated in the gelatine capsule of hard or soft shell, be compressed into the ingot sheet or directly add in experimenter's diet.For oral therapeutic administration, can with this anti-MAdCAM antibody and excipient be blended together and use with absorbable lozenge, buccal tablet, tablet, capsule, elixir, suspending agent, syrup, wafer and suchlike form.For by non-administration The compounds of this invention outside intestinal, have necessary this chemical compound of usefulness one coated materials or with this chemical compound co-administered to prevent its inactivation.

The present composition can comprise the antibody of the present invention or the antigen-binding portion thereof of " treatment effective dose " or " prevention effective dose "." treatment effective dose " is meant the amount of effectively reaching the expectation therapeutic effect in required period with required dosage.The treatment effective dose of an antibody or an antibody part can be with following factors vary: the ability that causes the reaction of expectation such as morbid state, Individual Age, sex and body weight and antibody or antibody moiety in this individuality body.The treatment effective dose still wherein the treatment beneficial effect of antibody or antibody moiety greater than the amount of its any toxicity or illeffects." prevention effective dose " is meant the amount of effectively reaching the expectation preventive effect in required period with required dosage.Usually, because preventive dose is before ill or illly is used for the experimenter in early days, so prevent effective dose can be less than the treatment effective dose.

Can be adjusted so that best expected response (for example, treatment or prophylactic response) to be provided dosage.For example, but the dense injecting of administration single, can or can reduce or increase dosage in proportion through several segmentation dosage of a period of time administration according to treatment situation urgency level is indicated.Allocating non-being particularly conducive to through the intestinal compositions with dosage unit form makes things convenient for administration and reaches the dosage concordance.The used dosage unit form of this description is meant and is suitable for as unit dose for intending being treated the physics separate unit that mammalian subject is used; Each unit comprises the reactive compound of the scheduled volume that can produce the expectation therapeutic effect as calculated and the combination of required medical carrier.The specification of dosage unit form of the present invention depends on and directly depends on following factors: (a) particular treatment or the preventive effect that reach of the peculiar property of anti-MAdCAM antibody or its part and wanting, and (b) allocate this antibody in the industry and occupy sex-limited with treatment individual sensitivity intrinsic.

The treatment of an antibody of the present invention or an antibody part or the prevention effective dose exemplary unrestricted scope be 0.025 to 50 milligram/kilogram, better be 0.1 to 50 milligram/kilogram, better be 0.1 to 25,0.1 to 10 or 0.1 to 3 milligrams/kilogram.In some embodiments, modulator contains 5 mg/ml antibody, is stored in and contains the 20mM sodium acetate, in the buffer of pH 5.5,140mM NaCl and 0.2 mg/ml polysorbate80.In other embodiment, for (for example) intravenous use, modulator contains 10 mg/ml antibody, is present in 2.73 mg/ml sodium acetate trihydrates, 45 mg/ml mannitol, 0.02 mg/ml, two water EDTA disodiums, the 0.2 mg/ml polysorbate80 (being adjusted to pH 5.5 with glacial acetic acid).In other embodiments, subcutaneous or the Intradermal purposes for (for example), modulator contain 50 mg/ml antibody, 2.73 mg/ml sodium acetate trihydrates, 45 mg/ml mannitol, 0.02 mg/ml, two water EDTA disodiums, 0.4 mg/ml polysorbate80 (being adjusted to pH 5.5 with glacial acetic acid).It should be noted that dose value can be with waiting that type and the seriousness of alleviating disease change.Should further understand: for arbitrary particular subject, should adjust concrete dosage at any time according to the individual's of individual need and administration composition or the administration of supervision group compound professional judgement, and the described dosage range of this description only by illustrating but not be intended to limit the scope or the application of opinion compositions.

In one embodiment, this antibody to be being the modulator administration of aseptic aqueous solution form, the pH of this aseptic aqueous solution between about 5.0 to about 6.5 and contain 1 mg/ml of having an appointment to the antibody of about 200 mg/ml, about 1 mM to about 100 mM histidine buffering liquids, about 0.01 mg/ml to about 10 mg/ml polysorbate80s, about 100 mMs to about 400 mM trehaloses and about 0.01 mM to about 1.0 mMs, two water EDTA disodiums.

Another aspect of the present invention provides the cover box that contains an anti-MAdCAM antibody of the present invention or an antibody part or contain the compositions of this antibody.Remove antibody or compositions overcoat box and can comprise diagnosis or therapeutic agent.The cover box can also comprise and be used to diagnose or the operation instruction of Therapeutic Method.In preferred embodiments, this cover box comprises antibody or contain the compositions of this antibody and the diagnostic agent that can use in following method.In the another one embodiment preferred, this cover box comprises this antibody or contain compositions and one or more therapeutic agents that can use of this antibody in following method.

Gene therapy

Be used for antibody of the present invention and can give the patient that these needs are arranged via the gene therapy administration.This therapy can be in vivo or the ex vivo mode carry out.In a preferred embodiment, give the patient with the two the nucleic acid molecules administration of encoding heavy chain and light chain.In a preferred embodiment, this nucleic acid molecules of administration so that its stable integration to the chromosome of B cell, because this cell can produce antibody specially.In a preferred embodiment, exsomatize transfection or infect precursor B cell and lay equal stress in neo-implanted patient's body that these needs are arranged.In another embodiment, use known interior precursor B cell or other cell of infecting of recombinant virions that infects the cells of interest type.The typical carriers that is used for gene therapy comprises liposome, plasmid and viral vector.Exemplary viral vector is retrovirus, adenovirus and adeno-associated virus.In the body or after the infection of exsomatizing, can and utilize known in the industry or the described immunoassay monitoring of this description antibody expression level by sampling in the treatment patient body of hanging oneself.

In a preferred embodiment, gene therapy comprises the separated nucleic acid molecules of administration coding anti-MAdCAM antibody heavy chain or its antigen-binding portion thereof and expresses the step of this nucleic acid molecules.In another embodiment, this gene therapy comprises the isolated nucleic acid molecule of administration coding anti-MAdCAM antibody light chain or one antigen-binding portion thereof and expresses the step of this nucleic acid molecules.At one more in the best method, this gene therapy comprise administration encode the isolated nucleic acid molecule of anti-MAdCAM antibody heavy chain of the present invention or its antigen-binding portion thereof and code book invention anti-MAdCAM antibody light chain or its antigen-binding portion thereof isolated nucleic acid molecule and express the step of this nucleic acid molecules.This gene therapy can also comprise the step of another antiinflammatory of administration or immunomodulator.

Anti-MAdCAM antibody is to α ₄β ₇The adherent inhibition of/MAdCAM dependency:

The present invention also provides in conjunction with MAdCAM and has suppressed to have α ₄β ₇The cell of-integrin to MAdCAM or other cognate ligand (select such as L-plain) to the combination of MAdCAM and the purposes of adherent anti-MAdCAM antibody.In a preferred embodiment, this MAdCAM is people MAdCAM and is soluble form or expresses on cell surface.In another preferred embodiment, this anti-MAdCAM antibody is people's antibody.In another embodiment, this antibody or its part suppress α ₄β ₇With combining between the MAdCAM, wherein IC ₅₀Value is no more than 50nM.In a preferred embodiment, this IC ₅₀Value is no more than 5nM.In a preferred embodiment, this IC ₅₀Value is less than 5nM.In a preferred embodiment, IC ₅₀Value is less than 0.05 mcg/ml, 0.04 mcg/ml or 0.03 mcg/ml.In another preferred embodiment, this IC ₅₀Value is less than 0.5 mcg/ml, 0.4 mcg/ml or 0.3 mcg/ml.This IC ₅₀Value can be by known arbitrary method measurement in the industry.Usually, IC ₅₀Value can or adhere to analysis to measure by ELISA.In a preferred embodiment, this IC ₅₀Value is to measure by adhering to analyze the cell or tissue that uses natural expression MAdCAM or made up the cell or tissue that can express MAdCAM.

Unless this description defines in addition, have and be the common implication of understanding of those of ordinary skill in the industry otherwise be used for science of the present invention and technical term.And,, should comprise singulative otherwise single term should comprise plural form and plural term unless context has requirement in addition.Generally speaking, be used for the term of the described cell of this description and tissue culture, molecular biology, immunology, microbiology, hereditism, protein and nucleic acid chemistry and hybridization and technology for knowing in the industry and commonly used.Except as otherwise noted, otherwise various versatilities that method of the present invention and technology generally can be quoted everywhere and discuss according to the traditional method of knowing in the industry with as description of the present invention and implementing described in the list of references more specifically.Referring to for example, people such as Sambrook, MolecularCloning:A Laboratory Manual, second edition, Cold Spring HarborLaboratory Press, Cold Spring Harbor, N.Y. people such as (1989) and Ausubel, Current Protocols in Molecular Biology, Greene PublishingAssociates (1992), and Harlow and Lane, Antibodies:A LaboratoryManual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1990), these documents are introduced in this description with way of reference.Enzymatic reaction and purification technique are implemented according to preparation merchant's description, or as traditional methods enforcement in the industry, or implement as described in this manual.Chemicals is synthetic, chemicals analysis, medication preparation, allocate and send, and patient's treatment adopt standard technique.

Polypeptide analog natural or synthetic protein, protein fragments and protein sequence contained in term " polypeptide ".Polypeptide can be monomer or polymer.

Term " through isolated protein " or " through isolated polypeptide " are according to its origin or derived from following protein or polypeptide: (1) with originally under its native state, do not follow the natural of its to combine in conjunction with component, (2) do not contain other protein from same species; (3) can be by cellular expression from different plant species; Or (4) do not exist under native state.Therefore, through chemosynthesis or be different from the cell system of cell of the natural origin of polypeptide synthetic polypeptide and naturally " separate " in conjunction with component with it.Also can utilize the purified technology of protein of knowing in the industry to make the protein cardinal principle not contain natural by separating in conjunction with component.

When a sample represent the single kind polypeptide at least about 60 to 75% the time, protein or polypeptide are " essence is pure ", " essence homogeneous " or " through the essence purification ".This polypeptide or protein can be monomer or polymer.Pure polypeptide of essence or protein can account for about 50%, 60%, 70%, 80% or the 90%W/W, more generally about 95% of protein example usually, and preferably can be 99% above purity.Lipidated protein or homogeneity can be represented by the multiple mode of knowing in the industry, for example carry out the polyacrylamide gel electrophoresis of protein example, are estimating single polypeptide band when stain dyes gel with knowing in the industry subsequently.For some purpose, can carry out purification by HPLC or other method of knowing in the industry provides higher definition.

Be meant polypeptide as the used term of this description " polypeptide fragment ", but wherein remaining aminoacid sequence is identical with the natural relevant position that exists in the sequence with amino terminal disappearance and/or carboxyl-terminal deletion.In certain embodiments, fragment is at least 5,6,8 or 10 amino acid longs.In other embodiments, at least 14 amino acid longs of this fragment, better at least 20 amino acid longs, at least 50 amino acid longs usually, further preferred at least 70,80,90,100,150 or 200 amino acid longs.

The used term of this description " polypeptide analog " is meant and comprises at least 25 the amino acid whose segmental polypeptide that contain that the part with the monoamino-acid sequence has the essence concordance and has at least a following character: (1) can be fit to specific bond MAdCAM under the bonded condition; (2) suppress α ₄β ₇Integrin and/or L-select plain ability in conjunction with MAdCAM; Or (3) reduce in vitro or the ability of the cell surface expression of MAdCAM in vivo.Usually, contain conserved amino acid replacement (or inserting or disappearance) with respect to the natural sequences polypeptide analog that exists.Analog is at least 20 amino acid longs, preferred at least 50,60,70,80,90,100,150 or 200 amino acid longs or longer usually, and normal the same long with the naturally occurring polypeptide of total length.

" immunoglobulin " is tetramer molecule.In naturally occurring immunoglobulin, each tetramer is made of two pairs of identical polypeptide chains, and each is to having " gently " chain (about 25kDa) and " weight " chain (about 50 to 70kDa).The amino terminal of every chain partly comprise one main be responsible for antigen recognition have about 100 to 110 or the variable region of amino acids more.The carboxyl terminal of every chain partly defines the main constant region of being responsible for effector function.People's light chain is categorized as κ light chain and lambda light chain.Heavy chain can be categorized as μ, δ, γ, α or ε, and the isotype of antibody is defined as IgM, IgD, IgA and IgE respectively.In light chain and heavy chain, variable region and constant region be via contain by about 12 or more a plurality of amino acid whose " J " district connect, wherein this heavy chain also comprises and containing by about 10 or more a plurality of amino acid whose " D " district.Usually referring to, FundamentalImmunology Ch.7 (Paul, W. edits, second edition, Raven Press, N.Y. (1989)) (for all purposes, its full content is introduced in this description with way of reference).The right variable region of each light chain/heavy chain forms antibody combining site so that immunoglobulin has two binding sites.

Immunoglobulin chain shows to have the identical universal architecture of conservative framework region (FR) relatively by three hypervariable regions (also being called complementary determining region or CDR) connection.CDR from each two right chain is arranged in a straight line to form epi-position specific bond site by framework region.To the C-end, light chain and heavy chain all comprise domain FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4 from the N-end.The distribution of aminoacid in each domain meets Sequences ofProteins of Immunological Interest (National Institutes ofHealth, Bethesda, Md. (1987 and 1991)) or the Chothia of Kabat; Lesk J.Mol.Biol.196:901-917 (1987); People such as Chothia, Nature, the definition of 342:878-883 (1989).

" antibody " is meant complete immunoglobulin or refers to and can compete bonded its antigen-binding portion thereof of specificity with complete antibody.In certain embodiments, antibody is its antigen-binding portion thereof.Fab is to produce by recombinant DNA technology or by enzymatic or chemical cracking complete antibody.Antigen-binding portion thereof especially comprises Fab, Fab ', F (ab ') ₂, Fv, dAb and complementary determining region (CDR) fragment, single-chain antibody (scFv), chimeric antibody, double antibody and contain the polypeptide of an immunoglobulin part (this immunoglobulin part is enough to give this polypeptide with the specific antigen binding ability) at least.The unit price fragment that the Fab fragment is made of VL, VH, CL and CH1 domain; F (ab) ₂Fragment contains the segmental bivalence fragment of two Fab that is connected by disulfide bond at hinge region; The Fd fragment is made of VH and CH1 domain; The Fv fragment is made of the VL and the VH domain of antibody single armed; And dAb fragment (people such as Ward, Nature, 341:544-546 (1989)) is made of the VH domain.

The antibody that this description is used to be called (for example) 1.7.2,1.8.2,6.14.2,6.34.2,6.67.1,6.77.2,7.16.6,7.20.5,7.26.4 or 9.8.2 is the monoclonal antibody that is generated by the hybridoma with same name.For example, antibody 1.7.2 is produced by hybridoma 1.7.2.The antibody that is called 6.22.2-mod, 6.34.2-mod, 6.67.1-mod, 6.77.1-mod or 7.26.4-mod is that its sequence is with the monoclonal antibody of direct mutagenesis modification from its corresponding parent.

Single-chain antibody (scFv) is its VL and VH district via making its synthetic connexon pairing that becomes single protein chain form antibody (people such as Bird of monovalent molecule, Science, people such as 242:423-426 (1988) and Huston, Proc.Natl.Acad Sci.USA, 85:5879-5883 (1988)).Double antibody is a bivalent, bispecific antibodies, wherein VH and VL domain are expressed on the single polypeptide chain, but used connexon is lacked very much thereby is not allowed on the same chain and match between two domains, thereby force the complementary structure territory pairing of such domain and another chain and form two antigen binding sites (referring to for example, Holliger, P. wait the people, Proc.Natl.Acad Sci.USA, 90:6444-6448 (1993); Poljak, people such as R.J., Structure, 2:1121-1123 (1994)).Covalently or non-covalently mode is introduced a molecule so that but it becomes the immunoadhesin of specific bond MAdCAM with one or more CDR from antibody of the present invention.Immunoadhesin can be introduced the part of CDR as big polypeptide chain; Can covalently bound CDR to become another polypeptide chain; Or can non-covalent mode introduce CDR.This CDR can make the immunoadhesin specificity be bonded to specific interested antigen.

Antibody can have one or more binding sites.If there is more than one binding site, then this binding site can be mutually the same or inequality.For example, naturally occurring immunoglobulin has two identical binding sites, and single-chain antibody or Fab fragment have a binding site, and " bispecific " or " difunctional " antibody (double antibody) then has two different binding sites.

" isolated antibody " is following antibody: (1) does not follow the natural of its to combine in conjunction with component (comprising other natural bonded antibody) under its native state with script, and (2) do not contain other protein from same species; (3) can be by cellular expression from different plant species; Or (4) do not exist under native state.The example of isolated antibody comprises the anti-MAdCAM antibody that utilizes the MAdCAM affinity purification, the anti-MAdCAM antibody that has been produced by hybridoma or other cell line in vitro and is derived from transgene mammal or people's anti-MAdCAM antibody of plant.

The used term of this description " people's antibody " means wherein, and variable region and constant region sequence antibody are human sequence's antibody.This term is contained to have and is derived from people's gene but reduces possible immunogenicity for (for example), increase affinity, eliminate the antibody of the sequence that may cause that the folding cysteine do not expected or glycosylation site etc. have changed.These antibody that reorganization produces in inhuman cell (its may give do not have the glycosylation of people's cell characteristic) contained in this term.The antibody of having raised also contained in this term in the transgenic mice that contains some or all of human immunoglobulin heavy chains and light chain gene seat.

On the one hand, the invention provides humanized antibody.In certain embodiments, this humanized antibody is the antibody that is derived from inhuman species, and some aminoacid has been accepted sudden change so that avoid or eliminate the intravital immunoreation of people in the framework of this heavy chain of antibody and light chain and the constant domain.In certain embodiments, humanized antibody can produce by making to merge from the constant domain of people's antibody and variable domains from inhuman species.The example that how to form humanized antibody is found in United States Patent (USP) the 6th, 054, and No. 297, the 5th, 886, No. 152 and the 5th, 877, No. 293.In certain embodiments, humanization anti-MAdCAM antibody of the present invention contains the aminoacid sequence of one or more framework regions of one or more people's anti-MAdCAM antibodies of the present invention.

In another aspect, the present invention includes the purposes of " chimeric antibody ".In certain embodiments, this chimeric antibody be meant contain one or more from an antibody the zone and contain the antibody in one or more zones from one or more other antibody.In a preferred embodiment, one or more CDR are derived from people's anti-MAdCAM antibody of the present invention.In a better embodiment, all CDR are derived from people's anti-MAdCAM antibody of the present invention.In a further advantageous embodiment, this CDR from more than one people's anti-MAdCAM antibody of the present invention is mixed in a chimeric antibody and match.For example, chimeric antibody can contain the CDR1 from first people's anti-MAdCAM antibody light chain, and this CDR1 can make up with CDR2 and the CDR3 from second people's anti-MAdCAM antibody light chain, and the CDR of heavy chain can be derived from the 3rd anti-MAdCAM antibody.In addition, framework region can be derived from the framework region of identical anti-MAdCAM antibody, one or more different antibodies (such as people's antibody) or humanized antibody.

" neutralizing antibody ", " blocking antibody " or antagonist antibodies are the α that can suppress at least about 20% ₄β ₇Or α ₄β ₇-express cell or any other cognate ligand or cognate ligand express cell are in conjunction with the antibody of MAdCAM.In a preferred embodiment, this antibody is to α ₄β ₇Integrin or α ₄β ₇The bonded inhibition of express cell and MAdCAM is at least 40%, better 60%, further preferred 80%, 85%, 90%, 95% or 100%.Can measure by any method known to those skilled in the art in conjunction with reducing, for example,, measure α as measuring by in vitro competing binding analysis ₄β ₇The example that express cell reduces the result of MAdCAM is shown in embodiment 1.

The instruction that those skilled in the art abides by this description can prepare antibody fragment or analog at an easy rate.Near the preferred amino of fragment or analog-reach carboxyl-end to appear at the functional domain frontier district.Nucleotide and/or amino acid sequence data and disclosed or patent all sequences data base can be compared and determine structure and functional domain by this.Preferably, determine to have sequence motifs or the expection protein conformation domain that occurs in the protein of known structure and/or function with the computerization comparative approach at other.The method that discriminating can be folded into the protein sequence of known three dimensional structure is people known people such as (, Science, 253:164 (1991)) Bowie.

Term " k _Off" refer to be used to characterize antibody from the dissociative dissociation rate constant of antibody/antigen complex.

Term " K _d" refer to the dissociation constant of specific antibodies-AI.It is said antibody at dissociation constant≤1 μ M, preferred≤100nM and most preferably≤can combine with antigen during 10nM.

Term " epi-position " comprise can the specific bond binding domain-immunoglobulin T-cell receptors or otherwise with the interactional any protein determinant of a part.The epi-position determinant is made up of the chemically reactive surface group (for example, aminoacid or carbohydrate side chain) of molecule usually, and it has specificity Three Dimensions Structure and specificity charge characteristic usually.The An epi-position can be " linearity " or " conformation " form.In linear epitope, all interaction points all occur with linear mode along the main aminoacid sequence of this protein between protein and the interacting molecule (such as antibody).In comformational epitope, the interaction point cross occurrence is on the amino acid residue that is separated from each other on the protein.

Used as this description, known usage is followed in 20 kinds of known aminoacid and abbreviation thereof.Referring to Immunology-A Synthesis (the 2nd edition, E.S.Golub and D.R.Gren edit, Sinauer Associates, Sunderland, Mass. (1991)), it is introduced in the patent specification by reference.20 kinds of known amino acid whose stereoisomers (for example D-aminoacid), alpha-non-natural amino acid (for example α-, α-disubstituted amino acid, N-alkyl amino acid), lactic acid, and other non-known aminoacid also be applicable to the component of polypeptide of the present invention.Non-known amino acid whose example comprises: 4-Hydroxyproline, γ-carboxyl bran propylhomoserin, ε-N; N; N-trimethyl lysine, ε-N-acetyl group lysine, O-phosphoserine, N-acetyl group serine, N-formoxyl methionine, 3-Methyl histidine, 5-oxylysine, s-N-methylarginine, and other similar aminoacid and imino acid (for example, 4-hydroxyproline).In the used polypeptide symbol of this description, left-hand is to for amino terminal direction right-hand lay is the carboxyl terminal direction, conformance with standard usage and convention.

Mean nucleotide (or being the modified form of ribonucleotide or deoxyribonucleotide or arbitrary types of nuclear thuja acid) polymerized form with at least 10 base length as the mentioned term of this description " polynucleotide ".This term comprises strand and the double chain form of DNA.

Mean the polynucleotide of genome source, cDNA source or synthetic source or its a certain combination as the used term of this description " isolating polynucleotide ", according to its source, be somebody's turn to do " isolating polynucleotide ": (1) is not to combine in the polynucleotide that wherein can find these " isolating polynucleotide " under native state with all or part of, (2) but with mode of operation with one under native state its not connected polynucleotide be connected, or (3) occur as the part of big sequence in native state.

The mentioned term of this description " oligonucleotide " comprises natural existence and the modified nucleotide that exists the oligonucleotide bond to link together by natural existence and non-natural.Oligonucleotide is the polynucleotide subclass, and it has 200 bases or less in length usually.Preferred 10 to 60 bases of oligonucleotide are long and most preferably 12,13,14,15,16,17,18,19 or 20 to 40 bases are long.Oligonucleotide is strand normally, for example for probe; But oligonucleotide also can be double-stranded, for example for the structure of gene mutation body.Oligonucleotide of the present invention can be sense strand oligonucleotide or antisense strand oligonucleotide.

The mentioned term of this description " naturally occurring nucleotide " comprises deoxyribonucleotide and ribonucleotide.The mentioned term of this description " modified nucleotide " comprises and has modified or be substituted the nucleotide of glycosyl and like that.The mentioned term of this description " oligonucleotide key " comprises following oligonucleotide key, for example D2EHDTPA ester group, phosphordithiic acid ester group, seleno is phosphate-based, two selenos are phosphate-based, phenylamino D2EHDTPA ester group, phenylamino are phosphate-based, phosphamide ester group, and like that.Referring to for example, people such as LaPlanche, Nucl AcidsRes.14:9081 (1986); People such as Stec, J.Am.Chem.Soc.106:6077 (1984); People such as Stein, Nucl.Acids Res.16:3209 (1988); People such as Zon, Anti-CancerDrug Design 6:539 (1991); People such as Zon, Oligonucleotides andAnalogues:A Practical Approach, 87-108 page or leaf (F.Eckstein edits, Oxford University Press, Oxford England (1991)); People such as Stec, United States Patent (USP) the 5th, 151, No. 510; Uhlmann and Peyman, Chemical Reviews, 90:543 (1990), disclosure one way of reference of above-mentioned list of references and patent is introduced in the patent specification.Oligonucleotide can optionally comprise a label that is used to detect.

But " connect " sequence and both comprised that expression control sequenc with the gene of interest adjacency also comprised the trans or action at a distance expression control sequenc with the sense of control interest genes with mode of operation.The used term of this description " expression control sequenc " is meant for the expression that realizes the coded sequence that it connected and processes indispensable polynucleotide sequence.Expression control sequenc comprises suitable transcription initiation, termination, promoter and enhancer sequence; Effective RNA processing signal is such as montage and polyadenylation signal; Stablize the sequence of kytoplasm mRNA; Strengthen the sequence (that is Kozak concensus sequence) of transcribing efficient; Strengthen the sequence of protein stability; And when needing, comprise the sequence that can strengthen protein secreting.The character of this control sequence is looked host living beings and difference; In prokaryote, this control sequence generally includes promoter, ribosome binding site, reaches transcription terminator; In eukaryote, this control sequence generally comprises promoter and transcription terminator.Term " control sequence " is intended to comprise that (bottom line) all its existence are absolutely necessary assembly and can comprise that also its extra existence is the assembly of benefiting for expressing and processing, for example targeting sequencing and fusion partner sequence.

The used term of this description " carrier " desire refers to transport the nucleic acid molecules of connected another nucleic acid.One class carrier is " plasmid ", and it refers to wherein can be connected with the circular double stranded DNA ring of extra DNA section.Another kind of carrier is a viral vector, and wherein extra DNA section can be connected in the viral genome.Some carrier (bacteria carrier and the additive type mammal carrier that for example, have the antibacterial replication origin) can be incorporated self-replicating in the host cell of this carrier therein into.Other carrier (for example, non-add type mammal carrier) can be integrated into after incorporating host cell in the genome of host cell, duplicates with host genome by this.In addition, but some carrier can guide with the connected expression of gene of mode of operation.This description is called " recombinant expression carrier " (or abbreviate as " expression vector ") with these carriers.Usually, the expression vector that is used for recombinant DNA technology is the plasmid form usually.In this manual, because plasmid is the most frequently used carrier format,, " plasmid " be used interchangeably so reaching " carrier ".Yet the present invention desires to comprise the expression vector of other form that equivalent function can be provided, for example viral vector (for example, replication defect type retrovirus, adenovirus and adeno-associated virus).

The used term of this description " recombinant host cell " (or abbreviate as " host cell ") desire refers to wherein introduce the cell of recombinant expression carrier.Should be appreciated that this term not only desire refers to the particular subject cell but also refers to the filial generation of this cell.Because sudden change or environmental effect can make follow-up each generation that some change takes place, therefore, this filial generation in fact may be different with blast cell but still be covered by in the scope of the used term of this description " host cell ".

The mentioned term of this description " selective cross " means and can detect ground and combination specifically.Polynucleotide of the present invention, oligonucleotide and fragment thereof under minimized hybridization of the detected binding capacity that makes estimable and non-specific nucleic acid and wash conditions selective cross to nucleic acid chains.Discuss as known and this description in the industry, available " high preciseness " or " highly rigorous " condition realize the selective cross condition.An example of " high preciseness " or " highly rigorous " condition is to make polynucleotide with the following method of hatching of another polynucleotide, wherein polynucleotide can be fixed on solid (such as the film) surface, in the hybridization buffer that contains 6X SSPE or SSC, 50% Methanamide, 5X Denhardt reagent, 0.5%SDS, 100 mcg/ml degeneration fragmentation salmon sperm dnas, under 42 ℃ hybridization temperature, hatched 12 to 16 hours, use the lavation buffer solution washed twice that contains 1X SSC, 0.5%SDS down at 55 ℃ then.Can be referring to people such as Sambrook, above-mentioned document, 9.50-9.55 page or leaf.

Term with regard to the nucleotide sequence scope " percentage ratio sequence identity " refers to when comparing with regard to maximum concordance identical residue in two sequences.The length of sequence identity comparison can surpass one section contain at least about the nucleotide sequence of 9 nucleotide, usually at least about 18 nucleotide, more generally at least about 24 nucleotide, typical case at least about 28 nucleotide, more typical at least about 32 nucleotide and preferably at least about 36,48 or more a plurality of nucleotide.The multiple conforming different algorithm known in the industry of nucleotide sequence that can be used to measure is arranged.For example, (this is the program among the Wisconsin Package Version 10.3, Accelrys, San Diego, CA) next many nucleotide sequences can to use FASTA, GaD or Bestfit.The FASTA that comprises (for example) program FASTA2 and FASTA3 can provide best comparison and percentage ratio sequence identity (Pearson, the Methods Enzymol.183:63-98 (1990) that overlaps and distinguish between inquiry and the search sequence; Pearson, Methods Mol, Biol.132:185-219 (2000); Pearson, Methods Enzymol.266:227-258 (1996); Pearson, J.Mol.Biol.276:71-84 (1998); The document is introduced in the patent specification with way of reference).Except as otherwise noted, otherwise can use the default parameters that is used for specific program or algorithm.For example, can utilize FASTA with its default parameters (using word wide 6 and NOPAM factor) or utilize Gap to come percentage ratio sequence identity between the definite kernel nucleotide sequence with the default parameters that provides among its Wisconsin Package Version 10.3 (introducing in the patent specification) with way of reference for rating matrix.

Except as otherwise noted, otherwise mention that nucleotide sequence also comprises its complementary portion.Therefore should be appreciated that, mention that the nucleic acid molecules with particular sequence also comprises its complementary strand with its complementary series.

At molecular biology in the industry, researcher is used interchangeably term " percentage ratio sequence identity ", " percentage ratio sequence similarity " reaches " percentage ratio sequence homology ".In the application's case, these terms only have identical meanings to nucleotide sequence.

When mentioning nucleic acid or its fragment, term " substantially similarity " or " essence sequence similarity " expression, insert or deletion and another nucleic acid (or its complementary strand) carry out optimum when comparing with suitable nucleotide, at least about 85%, preferably at least about 90% and goodly have the nucleotide sequence concordance at least about 95%, 96%, 97%, 98% or 99% nucleotide base, to know sequence identity algorithm (such as FASTA, BLAST or Gap) measured by arbitrary as mentioned above.

When being used for polypeptide, term " essence concordance " means, when two peptide sequences utilize acquiescence room weighting most comparison to be arranged by (for example) program GAP or BESTFIT, the two have at least 75% or 80% sequence identity, preferably have at least 90% or 95% sequence identity, further preferably have at least 98% or 99% sequence identity.Preferably, incomplete same residue position is different because of conserved amino acid replaces." conserved amino acid replacement " is that wherein the monoamino-acid residue is had by another and similar chemical property arranged the amino acid residue of side chain (R group) of (for example, electric charge or hydrophobicity) is replaced such replacement.Generally speaking, the conserved amino acid replacement can the proteinic functional character of material change.Two or more aminoacid sequences replace in the situation about differing from one another because of conservative therein, can raise percentage ratio sequence identity or similarity to proofread and correct the conservative character that replaces.The method that is used to carry out this adjustment is known by those skilled in the art.Referring to for example, Pearson, Methods Mol.Biol.24:307-31 (1994), the document is introduced in the patent specification with way of reference.The amino acid whose example of respectively organizing with side chain that similar chemical property is arranged comprises: 1) aliphatic lateral chain: glycine, alanine, valine, leucine and isoleucine; 2) aliphatic hydroxyl side chain: serine and threonine; 3) amide containing side chain: agedoite and glutamine; 4) aromatic series side chain: phenylalanine, tyrosine and tryptophan; 5) basic side chain: lysine, arginine and histidine; And 6) sulfur-containing side chain: cysteine and methionine.Preferred conserved amino acid substituted radical is: Val-Leu-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic acid-aspartic acid and agedoite-glutamine.

Perhaps, conservative replacement is people such as Gonnet, Science, have in the PAM250 logarithm similarity matrix that discloses among the 256:1443-45 (1992) (introducing in the patent specification) with way of reference on the occasion of any change." moderate is conservative " replaces is any change that has nonnegative value in PAM250 logarithm similarity matrix.

The sequence similarity of polypeptide utilizes sequence analysis software to measure usually.Protein analysis software uses distributes to various replacements, disappearance and other modification similarity measurement coupling similar sequence of (comprising that conserved amino acid replaces).For example, GCG contains such as " Gap " and reaches " Bestfit " supervisor, can utilize this program to determine to be closely related between the polypeptide (such as the polypeptide from the different plant species organism) or sequence homology or sequence identity between wild-type protein and the one mutein with default value.Referring to for example, Wisconsin package Version 10.3.Also can use FASTA (program among the Wisconsin package Version 10.3) with acquiescence or the many peptide sequences of recommended parameter.FASTA (for example, FASTA2 and FASTA3) can provide the comparison and the percentage ratio sequence identity (Pearson (1990) in the best district that overlaps between inquiry and the search sequence; Pearson (2000)).When with sequence of the present invention when containing in a large number data base from the sequence of different organisms and compare, another optimization algorithm is computer program BLAST, especially blastp or tblastn (use default parameters).Referring to for example, people such as Altschul, J.Mol.Biol.215:403-410 (1990); People such as Altschul, Nucleic Acids Res.25:3389-402 (1997); The document is introduced in the patent specification with way of reference.

The length of carrying out the peptide sequence of homology comparison generally can be at least about 16 amino acid residues, usually at least about 20 residues, more generally at least about 24 residues, typical case at least about 28 residues and preferably more than about 35 residues.When search contains data base from the sequence of a large amount of different organisms, preferably go the comparing amino acid sequence.

The used term of this description " label " or " through labelling " are meant and mix another molecule in antibody.In one embodiment, this label is detectable label, for example, mix through radiolabeled aminoacid or be connected to have can be by the biotinyl part that detects through the labelling avidin polypeptide (for example, comprise fluorescent marker or have the Succ-PEG-DSPE of the enzymatic activity that can detect by optics or colorimetric method).In another embodiment, this labelling or label can be therapeutic agents, for example, and drug conjugate or toxin.The method of multiple labeling polypeptide and glycoprotein is for known in the industry and can use.The label example that is used for polypeptide includes but not limited to following each thing: radiosiotope or radionuclide are (for example, ³H, ¹⁴C, ¹⁵N, ³⁵S, ⁹⁰Y, ⁹⁹Tc, ¹¹¹Ln, ¹²⁵L, ¹³¹L), fluorescent marker (for example, FITC, rhodamine, the lanthanide series phosphor), the enzyme labelling thing (for example, peroxidase, beta galactosidase, luciferase, alkali phosphatase), chemiluminescent labels, the biotin group, by the sub predetermined polypeptide epitope of discerning of secondary report (for example, leucine zipper is to sequence, the binding site of secondary antibody, the melts combine domain, the epi-position label), the magnetic agent, such as gadolinium chelate compound, toxin is such as pertussis toxin, PT (pertussis toxin), paclitaxel (taxol), cytochalasin B (cytochalasin B), Gramicidin D (gramicidin D), ethidium bromide (ethidiumbromide), ipecine (emetine), mitomycin (mitomycin), show terrible Chinese tallow tree toxin (etoposide), teniposide (tenoposide), vincristine (vincristine), vinblastine (vinblastine), colchicine (colchicin), doxorubicin (doxorubicin), daunorubicin (daunorubicin), dihydroxyanthraquinone (dihydroxyanthracin dione), mitoxantrone (mitoxantrone), mithramycin (mithramycin), actinomycin D (actinomycin D), 1-boldenone (1-dehydrotestosterone), glucocorticoid, procaine (procaine), tetracaine (tetracaine), lignocaine (lidocaine), Propranolol (propranolol), and puromycin (puromycin) and analog or homologue.In certain embodiments, label adds potential sterically hindered to reduce by the introns arm of all lengths.

Claims

1. the purposes of an anti-MAdCAM antibody or its antigen-binding portion thereof, it is used to prepare the medicine that is used for treating celiac disease and/or ceylon sore mouth.

2. the purposes of claim 1, wherein this medicine is used for the treatment of celiac disease.

3. the purposes of claim 1 or claim 2, wherein this anti-MAdCAM antibody is a human monoclonal antibodies.

4. the purposes of claim 3, wherein this antibody or part have at least a following character:

(a) in conjunction with people's cell;

(c) with 3 * 10 ^-10M or lower K _dIn conjunction with people MAdCAM; Or

(d) suppress α ₄β ₇Express cell is to the combination of people MAdCAM;

(e) suppressing lymphocyte raises to gastrointestinal is adenoid.

5. each purposes in the claim 1 to 4, wherein said antibody or antigen-binding portion thereof suppress people MAdCAM to α ₄β ₇Combination, and wherein this antibody or its part have at least a following character:

(a) with reference to the antibody cross competition combine MAdCAM;

(b) with reference to antibody competition combine MAdCAM;

(c) with reference to the identical MAdCAM epi-position of antibodies;

6. each purposes in the claim 1 to 5, the wherein variable region of heavy chain of this anti-MAdCAM antibody, variable region of light chain or the two have at least 90% homogeneity: monoclonal antibody 1.7.2 with the corresponding region that is selected from following monoclonal antibody on aminoacid sequence, monoclonal antibody 1.8.2, monoclonal antibody 6.14.2, monoclonal antibody 6.22.2, monoclonal antibody 6.34.2, monoclonal antibody 6.67.1, monoclonal antibody 6.73.2, monoclonal antibody 6.77.1, monoclonal antibody 7.1 6.6, monoclonal antibody 7.20.5, monoclonal antibody 7.26.4, monoclonal antibody 9.8.2, monoclonal antibody 6.22.2-mod, monoclonal antibody 6.34.2-mod, monoclonal antibody 6.67.1-mod, monoclonal antibody 6.77.1-mod and monoclonal antibody 7.26.4-mod.

7. each purposes in the claim 1 to 6, wherein this antibody is selected from:

(a) contain the aminoacid sequence that is shown in SEQ ID NO:2 and SEQ ID NO:4 but the antibody that does not contain signal sequence;

(b) contain the aminoacid sequence that is shown in SEQ ID NO:6 and SEQ ID NO:8 but the antibody that does not contain signal sequence;

(c) contain the aminoacid sequence that is shown in SEQ ID NO:10 and SEQ ID NO:12 but the antibody that does not contain signal sequence;

(d) contain the aminoacid sequence that is shown in SEQ ID NO:14 and SEQ ID NO:16 but the antibody that does not contain signal sequence;

(e) contain the aminoacid sequence that is shown in SEQ ID NO:18 and SEQ ID NO:20 but the antibody that does not contain signal sequence;

(f) contain the aminoacid sequence that is shown in SEQ ID NO:22 and SEQ ID NO:24 but the antibody that does not contain signal sequence;

(g) contain the aminoacid sequence that is shown in SEQ ID NO:26 and SEQ ID NO:28 but the antibody that does not contain signal sequence;

(h) contain the aminoacid sequence that is shown in SEQ ID NO:30 and SEQ ID NO:32 but the antibody that does not contain signal sequence;

(i) contain the aminoacid sequence that is shown in SEQ ID NO:34 and SEQ ID NO:36 but the antibody that does not contain signal sequence;

(j) contain the aminoacid sequence that is shown in SEQ ID NO:38 and SEQ ID NO:40 but the antibody that does not contain signal sequence;

(k) contain the aminoacid sequence that is shown in SEQ ID NO:42 and SEQ ID NO:44 but the antibody that does not contain signal sequence;

(l) contain the aminoacid sequence that is shown in SEQ ID NO:46 and SEQ ID NO:48 but the antibody that does not contain signal sequence;

(m) contain the aminoacid sequence that is shown in SEQ ID NO:52 and SEQ ID NO:54 but the antibody that does not contain signal sequence;

(n) contain the aminoacid sequence that is shown in SEQ ID NO:56 and SEQ ID NO:58 but the antibody that does not contain signal sequence;

(o) contain the aminoacid sequence that is shown in SEQ ID NO:60 and SEQ ID NO:62 but the antibody that does not contain signal sequence;

(p) contain the aminoacid sequence that is shown in SEQ ID NO:64 and SEQ ID NO:66 but the antibody that does not contain signal sequence; And

(q) contain the aminoacid sequence that is shown in SEQ ID NO:42 and SEQ ID NO:68 but the antibody that does not contain signal sequence.

8. each purposes in the claim 1 to 7, wherein the lysine of heavy chain C-end is from this anti-MAdCAM antibody cracking.

9. each purposes in the claim 1 to 8, wherein this monoclonal antibody or its antigen-binding portion thereof are selected from following antibody:

(a) heavy chain comprises and is selected from following heavy chain CDR1, CDR2 and CDR3 aminoacid sequence: 1.7.2,1.8.2,6.14.2,6.22.2,6.34.2,6.67.1,6.73.2,6.77.1,7.16.6,7.20.5,7.26.4,9.8.2,6.22.2-mod, 6.34.2-mod, 6.67.1-mod, 6.77.1-mod and 7.26.4-mod with reference to antibody

(b) light chain comprises and is selected from following light chain CDR1, CDR2 and CDR3 aminoacid sequence: 1.7.2,1.8.2,6.14.2,6.22.2,6.34.2,6.67.1,6.73.2,6.77.1,7.16.6,7.20.5,7.26.4,9.8.2,6.22.2-mod, 6.34.2-mod, 6.67.1-mod, 6.77.1-mod and 7.26.4-mod with reference to antibody

(c) this antibody comprises the heavy chain of (a) and light chain (b); And

(d) antibody (c), wherein heavy chain and light chain cdr amino acid sequence are selected from identical with reference to antibody.

10. each purposes in the claim 1 to 9, wherein this monoclonal antibody or antigen-binding portion thereof comprise:

(a) contain the heavy chain of the weight chain variable region amino acid sequence that is selected from following antibody: 1.7.2 (SEQID NO:2); (1.8.2 SEQ ID NO:6); (6.14.2 SEQ ID NO:10); (6.22.2 SEQID NO:14); 6.3 4.2 (SEQ ID NO:18); 6.6 7.1 (SEQ ID NO:22); (6.73.2 SEQID NO:26); (6.77.1 SEQ ID NO:30); (7.16.6 SEQ ID NO:34); 7.2 0.5 (SEQID NO:38); 7.2 6.4 (SEQ ID NO:42); And 9.8.2 (SEQ ID NO:46); (6.22.2-mod SEQ ID NO:52); (6.34.2-mod SEQ ID NO:56); (6.67.1-mod SEQ ID NO:60); (6.77.1-mod SEQ ID NO:64); And 7.26.4-mod (SEQ ID NO:42);

(b) contain the light chain of the light chain variable region amino acid sequence that is selected from following antibody: 1.7.2 (SEQID NO:4); (1.8.2 SEQ ID NO:8); (6.14.2 SEQ ID NO:12); (6.22.2 SEQID NO:16); (6.34.2 SEQ ID NO:20); (6.67.1 SEQ ID NO:24); (6.73.2 SEQID NO:28); (6.77.1 SEQ ID NO:32); (7.16.6 SEQ ID NO:36); (7.20.5 SEQID NO:40); (7.26.4 SEQ ID NO:44); And 98.2 (SEQ ID NO:48); (6.22.2-mod SEQ ID NO:54); (6.34.2-mod SEQ ID NO:58); (6.67.1-mod SEQ ID NO:62); (6.77.1-mod SEQ ID NO:66); And 7.26.4-mod (SEQ ID NO:68); Or

(c) heavy chain (a) and light chain (b).

11. anti--α ₄β ₇The purposes of alpha 2 integrin antibodies or its antigen-binding portion thereof, it is used to prepare the medicine that is used for treating celiac disease and/or ceylon sore mouth.